
• Reported GAAP EPS of -$0.85 up 3.41% YoY • Reported revenue of -$0.03M down -100.96% YoY • Vir Biotechnology expects its cash, cash equivalents and investments, including effects of the Astellas collaboration and equity financing, to fund operations into the second half of 2028.
Bullish
Vir Biotechnology demonstrated strong financial health and advanced its pipeline with a key Astellas collaboration for VIR-5500 and positive Phase 2 data for its CHD combination regimen.
Bearish
Vir Biotechnology experienced an increased net loss and a significant decline in total revenues during Q1 2026, alongside the inherent high risks of drug development and commercialization.